for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Chromadex Corp

CDXC.OQ

Latest Trade

4.17USD

Change

-0.29(-6.50%)

Volume

112,932

Today's Range

4.16

 - 

4.44

52 Week Range

2.50

 - 

5.79

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
4.46
Open
4.44
Volume
112,932
3M AVG Volume
6.11
Today's High
4.44
Today's Low
4.16
52 Week High
5.79
52 Week Low
2.50
Shares Out (MIL)
61.62
Market Cap (MIL)
274.84
Forward P/E
-12.82
Dividend (Yield %)
--

Latest Developments

More

Chromadex Corporation Reports Second Quarter 2020 Financial Results

Chromadex And NIH-NIAID Rocky Mountain Laboratories Announce Study To Assess Therapeutic Potential Of Niagen® In Covid-19 Animal Models

ChromaDex Says An R&D Facility In Colorado Earns Accredition

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Chromadex Corp

Chromadex Corporation is an integrated nutraceutical company. The Company and its subsidiaries ChromaDex, Inc., ChromaDex Analytics, Inc. and Spherix Consulting, Inc. provides research and quality-control products and services to the natural products industry. The Company partners with universities and research institutions worldwide to discover, develop and create solutions to deliver the full potential of nicotinamide adenine dinucleotide (NAD) and its impact on human health. The Company’s operated segments are: Consumer Product, Ingredients, and Analytical Reference Standards and Service Segment. Its Consumer Product segment offers TRU NIAGEN to consumers worldwide. Its ingredients business segment develops and commercializes ingredients, including nicotinamide riboside (NR), for which its brand name is NIAGEN. It also develops pterostilbene, which is marketed and sold under its brand name, pTeroPure.

Industry

Biotechnology & Drugs

Contact Info

10900 Wilshire Blvd Ste 600

LOS ANGELES, CA

90024-6534

United States

+1.310.3886706

https://chromadex.com/default.aspx

Executive Leadership

Frank L. Jaksch

Executive Chairman of the Board

Robert N. Fried

Chief Executive Officer, Director

Kevin M. Farr

Chief Financial Officer

Megan Kern Jordan

Chief Communications Officer and Senior Vice President of Global Marketing

Mark Friedman

General Counsel, Corporate Secretary

Key Stats

1.60 mean rating - 5 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2017

0.0K

2018

0.0K

2019

0.0K

2020(E)

0.1K
EPS (USD)

2017

-0.260

2018

-0.610

2019

-0.560

2020(E)

-0.354
Price To Earnings (TTM)
--
Price To Sales (TTM)
5.02
Price To Book (MRQ)
12.69
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
0.75
LT Debt To Equity (MRQ)
0.13
Return on Investment (TTM)
-110.92
Return on Equity (TTM)
-59.32

Latest News

Latest News

BRIEF-Chromadex And NIH-NIAID Rocky Mountain Laboratories Announce Study To Assess Therapeutic Potential Of Niagen® In Covid-19 Animal Models

* CHROMADEX AND THE NIH-NIAID ROCKY MOUNTAIN LABORATORIES ANNOUNCE STUDY TO ASSESS THE THERAPEUTIC POTENTIAL OF NIAGEN® IN COVID-19 ANIMAL MODELS

BRIEF-Chromadex Says May Offer & Sell Shares Of Common Stock Of Up To $50 Mln From Time To Time, Pursuant To Sales Agreement, Dated June 12, 2020

* CHROMADEX - MAY OFFER & SELL SHARES OF COMMON STOCK OF UP TO $50 MILLION FROM TIME TO TIME, PURSUANT TO SALES AGREEMENT, DATED JUNE 12, 2020 Source text: [https://bit.ly/3hZkcPI] Further company coverage: (Reuters.Briefs@thomsonreuters.com)

BRIEF-ChromaDex Says An R&D Facility In Colorado Earns Accredition

* CHROMADEX SAYS ITS RESEARCH AND DEVELOPMENT FACILITY IN LONGMONT, COLORADO ACHIEVED A QUALITY STANDARD FOR LABORATORY TESTING Source text for Eikon: Further company coverage:

BRIEF-Chromadex Corp Files For Mixed Shelf Of Up To $125 Million – SEC Filing

* CHROMADEX CORP FILES FOR MIXED SHELF OF UP TO $125 MILLION – SEC FILING Source text for Eikon: https://bit.ly/2XXggqT Further company coverage:

BRIEF-Chromadex Says Selling Stockholders Offer And Resale Of Up To 1.23 Mln Shares Of Common Stock

* CHROMADEX CORP SAYS SELLING STOCKHOLDERS OFFER AND RESALE OF UP TO 1.23 MILLION SHARES OF COMMON STOCK - SEC FILING Source: (https://bit.ly/3csPquD) Further company coverage:

BRIEF-Chromadex Reports Publication Of Study Evaluating NAD Metabolome In Samples From People With Liver Diseases

* CHROMADEX - ANNOUNCED PUBLICATION OF STUDY EVALUATING NAD METABOLOME IN HUMAN LIVER SAMPLES FROM PEOPLE WITH LIVER DISEASES INCLUDING ALCOHOL-RELATED LIVER DISEASE Source text for Eikon: Further company coverage:

BRIEF-Chromadex Files For Offering Of Up To 1.23 Million Shares Of Common Stock By Selling Stockholders

* CHROMADEX CORP FILES FOR OFFERING OF UP TO 1.23 MILLION SHARES OF COMMON STOCK BY THE SELLING STOCKHOLDERS - SEC FILING Source text: (https://bit.ly/2XhvxBk) Further company coverage:

BRIEF-Chromadex Corp Files For Non Timely 10-Q - SEC Filing

* CHROMADEX CORP FILES FOR NON TIMELY 10-Q - SEC FILING Source text: https://bit.ly/2SYlorN Further company coverage:

BRIEF-ChromaDex Corporation Reports Q1 Loss Per Share $0.10

* Q1 SALES $14.3 MILLION VERSUS REFINITIV IBES ESTIMATE OF $13.8 MILLION

BRIEF-Chromadex Entered Into Securities Purchase Agreement With Winsave Resources, Pioneer Step

* CHROMADEX CORP - ON APRIL 27, ENTERED INTO A SECURITIES PURCHASE AGREEMENT WITH WINSAVE RESOURCES LIMITED AND PIONEER STEP HOLDINGS LIMITED

BRIEF-Chromadex And Watsons Launch New Tru Niagen Beauty Cellular Nutrient In Hong Kong

* CHROMADEX AND WATSONS LAUNCH NEW TRU NIAGEN® BEAUTY CELLULAR NUTRIENT IN HONG KONG, BROADENING GLOBAL RETAIL PARTNERSHIP Source text for Eikon: Further company coverage:

BRIEF-Elysium Health Loses Appeal Of Patent Challenge Decision, Upholding Validity Of Chromadex Intellectual Property

* ELYSIUM HEALTH, INC. LOSES APPEAL OF PATENT CHALLENGE DECISION, UPHOLDING VALIDITY OF CHROMADEX INTELLECTUAL PROPERTY

BRIEF-Chromadex Says There Are No Published Human Clinical Studies Evaluating Effects Of Tru Niagen Supplementation With Coronavirus

* CHROMADEX CORP - THERE ARE NO PUBLISHED HUMAN CLINICAL STUDIES EVALUATING EFFECTS OF TRU NIAGEN SUPPLEMENTATION WITH CORONAVIRUS

BRIEF-Chromadex Posts Quarterly Loss Per Share Of $0.15

* Q4 SALES $13.1 MILLION VERSUS REFINITIV IBES ESTIMATE OF $12.9 MILLION

BRIEF-Chromadex Partners With Personalized Nutrition Company, Persona Nutrition, Expanding Global Partnership With Nestlé Health Science

* CHROMADEX PARTNERS WITH PERSONALIZED NUTRITION COMPANY, PERSONA NUTRITION, EXPANDING GLOBAL PARTNERSHIP WITH NESTLÉ HEALTH SCIENCE Source text for Eikon: Further company coverage:

BRIEF-Chromadex Q1 Loss Per Share $0.15

* Q1 SALES ROSE 95 PERCENT TO $6.6 MILLION Source text for Eikon: Further company coverage:

BRIEF-Chromadex Corp Appoints Rob Fried as Chief Executive Officer

* CHROMADEX APPOINTS FRANK JAKSCH AS EXECUTIVE CHAIRMAN, ROB FRIED AS CHIEF EXECUTIVE OFFICER AND KURT GUSTAFSON AS LEAD DIRECTOR

BRIEF-Chromadex Corporation Q4 Loss Per Share $0.17

* Q4 REPORTED LOSS FROM CONTINUING OPERATIONS NEGATIVELY IMPACTED BY NON-CASH CHARGE OF $3.4 MILLION RELATED TO STOCK-BASED COMPENSATION

BRIEF-Chromadex Chairman Stephen Allen Will Retire From The Board

* CHROMADEX CHAIRMAN STEPHEN ALLEN WILL RETIRE FROM BOARD OF DIRECTORS

BRIEF-ChromaDex Corp Sees Q4 2017 Revenue About $7.5 Mln

* AN OPERATING LOSS FOR Q4 OF 2017 IS EXPECTED TO BE IN A RANGE OF $8.5 MILLION TO $9.5 MILLION

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up